BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock News
NASDAQ:DRUG - Nasdaq - CA10919W4056 - Common Stock - Currency: USD
DRUG Latest News, Press Relases and Analysis
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - ...
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected...
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data.
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the...
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”)...
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
Biotechs on the Brink: 2 Stocks With Huge Potential
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE...
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) --...
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery.
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”)...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN...
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models ...
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is excited to announce its participation in the upcoming scientific conferences...
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences will host the Key Opinion Leader event with leading experts in epilepsy research and treatment on September 25...